ctespro.icu

Radiotherapy, also known as radiation therapy, uses ionizing radiations that deliver targeted beams of radiation to kill and destroy cancer cells. The advanced technology used in radiotherapy works by bombarding cancerous cells with radiation to kill them, while minimizing damage to the healthy cells around them. Radiotherapy is the most potent and cost-effective treatment for cancer, and when integrated with advanced technologies such as image guided therapy, leads to enhanced control over tumor and toxicity.

Click To Continue Reading on Radiotherapy Market

Several types of radiotherapies such as external beam radiation therapy, internal beam radiation therapy/ brachytherapy, and systemic radiation therapy, are available to combat various types of cancers prevalent globally. External beam radiation therapy is used to treat various types of cancers, including brain tumors, bladder cancer, and bone cancers. Brachytherapy is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye, while systemic radiation therapy is often used to treat certain types of thyroid cancers using radioactive iodine.

Rising prevalence of oncology diseases such as prostate cancer, lung cancer, and breast cancer, globally is increasing the demand for timely management to reduce mortality associated with such conditions. This in turn, is a major factor augmenting growth of the radiotherapy market. The International Cancer Association, 2014, states that cancer kills more people every year than AIDS, tuberculosis, and malaria combined. This indicated the growing demand for adopting advanced technologies for cancer management.

According to the World Cancer Research Fund Organization, 2015, lung cancer is among the most prevalent cancers worldwide contributing 1.9 million or 13% of the total number of new cases diagnosed in 2012. It further states that breast cancer is the second most common cancer prevalent among women, with 1.7 million new cases diagnosed in 2012. Moreover, increasing prevalence of cancer among children is expected to increase the demand for radiation therapy, as it is a highly recommended therapy due to fewer adverse effects associated with it than chemotherapy to accelerate growth of the market as considering the major adverse effects of chemotherapy. According to the International Union against Cancer (UICC) Report, 2017, around 160,000 children are estimated to be diagnosed with cancer and at least 90,000 children are estimated to die of cancer globally.

Parenteral are sterile dosage form that are administered through route other than oral route of administration. They are injected into one or more layer of skin and active ingredient directly come in contact with tissue or blood vessel. Large volume parenteral are of two types, small volume parenteral are single or multi dosage preparation with volume 100 ml or less quantity whereas large volume parenteral has volume more than 100 ml. Large volume parenteral comes in bag or bottle for intravenous administration and are used for correction of fluid/electrolyte balance, providing nutrition such as dextrose.

Click To Continue Reading on Large Volume Parenteral Market

Increasing demand for palliative care worldwide is expected to drive growth of the large volume parenteral market, owing to use of large volume parenteral to provide electrolyte balance and nutritional fluids. According to World Health Organization (WHO), 2017, an estimate of 40 million people need palliative care worldwide. Around 78% among those people, live in low- and middle-income economies and only 14% of people in need of palliative care receives it. Disease which require high palliative care are cardiovascular diseases (38.5%), cancer (34%), chronic respiratory diseases (10.3%), AIDS (5.7%) and diabetes (4.6%), kidney failure, chronic liver disease.

This creates potential opportunity for large volume parenteral market players. Increasing number of surgeries are expected to propel growth for the large volume parenteral market worldwide. For instance, according to World Bank statistics, in 2012, around 4511 surgeries were performed per 1,00,000 population across the globe. As per Lancet Commission for Global Surgery, 2015, an estimate of 143 million unmet surgical need per year, surgical need in turn drives large volume parenteral market as they are essential part of pre and post-operative care.

Regional segmentation of the large volume parental market by Coherent Market Insights consist of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate the large volume parenteral market, owing to increasing number of hospital admissions and cost associated with such admission (an estimated US$ 1900 in 2013 as per Kaiser Health fact). According to American Hospital Association factsheet 2018, an estimated 35,158,934 hospital admissions were reported in 2017, large volume parenteral is integral part of any admission procedure, as nutrition and electrolyte support is essential in most of the cases.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1323

Key Vendors:

Baxter International Inc., Teva Pharmaceutical Industries Limited, Kelun Pharmaceutical Inc., BAG Healthcare GmbH, Hospira, Inc., Patheon Inc., Otsuka Pharmaceutical, Wockhardt Ltd., Southwest Pharmaceutical Co. Ltd., and Cook Pharmica LLC.